Therapeutic drug monitoring

Nephrology

Volumn 12, Issue SUPPL. 1, 2007, Pages

  Trevillian, Paul ^a  

^a JOHN HUNTER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; CYCLOSPORIN A; DILTIAZEM; PREDNISONE; STEROID; TACROLIMUS; CALCINEURIN; IMMUNOSUPPRESSIVE AGENT;

AREA UNDER THE CURVE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MONITORING; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; DRUG ANTAGONISM; PRACTICE GUIDELINE;

CALCINEURIN; CYCLOSPORINE; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION;

EID: 33846958702     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2007.00730.x     Document Type: Review

References (42)

1. Kasiske BL, Heim-Duthay K, Rao KV et al. The relationship between cyclosporin pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. Transplantation 1988; 46: 716-22.
2. Kahan BD, Welsh M, Schoenberg L et al. Variable oral absorption of cyclosporin. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 1996; 62: 599-606.
3. David OJ, Johnston A. Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: Review of current algorithms. Ther. Drug Monit. 2001; 23: 100-14.
4. International Neoral Renal Transplantation Study Group. Randomized, international study of cyclosporin microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am. J. Transplant. 2002; 2: 157-66.
5. 2). Transplantation 2002; 73: 953-59.
6. Buchler M, Chadban S, Rodriguez A, Jost L, Weber M, Cole E. Improved Efficacy and Tolerability of Neoral By C2 Monitoring iln De Novo Renal Transplant Recipitents (Abstract). Nephrol. Dial. Transplant 2003; 18: 779-89.
7. 2 monitoring in de novo renal transplant recipients: Retrospective analysis of a single-center experience. Transplantation 2004; 78: 1787-91.
8. Oellerich M, Armstrong VW, Kahan B et al. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: Report of the consensus panel. Ther. Drug Monit. 1995; 17: 642-54.
9. Balbontin FG, Kiberd B, Squires J et al. Tacrolimus monitoring by simplified sparse sampling under the concentration time curve. Transplant Proc. 2003; 35: 2445-8.
10. Mathias H, Ozalp F, Will M, Borland W, Payne C, Kerr M, Lochkart J, Murday A. A ranomized controlled trial of C0- vs C2-guided therapeutic drug monitoring of a cyclosporin in stable heart transplant patients. Journal of Heart and Lung Transplantation 2005; 24: 2137-43.
11. 2 monitoring in stable renal allograft recipients on maintenance immunosuppression. Nephrol. Dial. Transplant. 2004; 19: 215-22.
12. 2 level for chronic renal allograft dysfunction. Transplant. Proc. 2003; 35: 2894-8.
13. Pape L, Lehnhardt A, Latta K et al. Cyclosporin A monitoring by 2-h levels: Preliminary target levels in stable pediatric kidney transplant recipients. Clin. Transplant. 2003; 17: 546-8.
14. David-Neto E, Lemos FB, Furusawa EA et al. Impact of cyclosporin A pharmacokinetics on the presence of side effects in pediatric renal transplantation. J. Am. Soc. Nephrol. 2000; 11: 343-9.
15. 2 concentrations. Transplant. Proc. 2004; 36: 437S-41S.
16. 2 level as a marker for absorption. Pediatr. Transplant. 2003; 7: 282-8.
17. Jaiswal J, Gupta SK, Dash SC et al. Neoral monitoring by limited sampling area under the concentration time curve in stable Indian renal transplant recipients. Transplant. Proc. 2003; 35: 1298-9.
18. Felipe CR, Silva HT Jr, Machado PG et al. Time-dependent changes in cyclosporin exposure: Implications for achieving target concentrations. Transpl. Int. 2003; 16: 494-503.
19. David-Neto E, Araujo LP, Feres Alves C et al. A strategy to calculate cyclosporin A area under the time-concentration curve in pediatric renal transplantation. Pediatr. Transplant. 2002a; 6: 313-18.
20. David-Neto E, Araujo LM, Brito ZM et al. Sampling strategy to calculate the cyclosporin-A area under the time-concentration curve. Am. J. Transplant. 2002b; 2: 546-50.
21. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporin microemulsion (neoral) during the first 2 weeks after renal transplantation. Transplantation 2001; 72: 1024-32.
22. Wacke R, Rohde B, Engel G et al. Comparison of several approaches of therapeutic drug monitoring of cyclosporin A based on individual pharmacokinetics. Eur. J. Clin. Pharmacol. 2000; 56: 43-8.
23. Tam JC, Earl JW, Willis NS et al. Pharmacokinetics of cyclosporin in children with stable renal transplants. Pediatr. Nephrol. 2000; 15: 167-70.
24. Kelles A, Herman J, Tjandra-Maga TB et al. Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients. Pediatr. Transplant. 1999; 3: 282-7.
25. Meier-Kriesche HU, Kaplan B, Brannan P et al. A limited sampling strategy for the estimation of eight-hour Neoral areas under the curve in renal transplantation. Ther. Drug Monit. 1998; 20: 401-7.
26. Primmett DR, Levine M, Kovarik JM et al. Cyclosporin monitoring in patients with renal transplants: Two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure. Ther. Drug Monit. 1998; 20: 276-83.
27. Gaspari F, Anedda MF, Signorini O et al. Prediction of cyclosporin area under the curve using a three-point sampling strategy after Neoral administration. J. Am. Soc. Nephrol. 1997; 8: 647-52.
28. Felipe CR, Silva HT, Machado PG, Garcia R, da Silva Moreira SR, Pestana JO. The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring. Clin. Transplant 2002; 16: 262-72.
29. 2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol. Dial. Transplant. 2002; 17: 1487-90.
30. Filler G, Feber J, Lepage N et al. Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children. Pediatr. Transplant. 2002; 6: 411-18.
31. Wong KM, Shek CC, Chau KF et al. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am. J. Kidney Dis. 2000; 35: 660-6.
32. Ihara H, Shinkuma D, Ichikawa Y et al. Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients - importance of trough level as a practical indicator. Int. J. Urol. 1995; 2: 151-5.
33. 2 monitoring of cyclosporin microemulsion. Transplantation 2003; 76: 903-8.
34. Clase CM, Mahalati K, Kiberd BA et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: Patients monitored by absorption profiling. Am. J. Transplant. 2002; 2: 789-95.
35. Pescovitz MD, Barbeito R, Simulect USOI Study Group. Two-hour post-dose cyclosporin level is a better predictor than trough level of acute rejection of renal allografts. Clin. Transplant. 2002; 16: 378-82.
36. Morris RG, Russ GR, Cervelli MJ et al. Comparison of trough, 2-h, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther. Drug Monit. 2002; 24: 479-86.
37. Mahalati K, Belitsky P, West K et al. Approaching the therapeutic window for cyclosporin in kidney transplantation: A prospective study. J. Am. Soc. Nephrol. 2001; 12: 828-33.
38. 2 monitoring in stable renal transplant recipients: A prospective single center study. J. Nephrol. 2004; 17: 284-90.
39. 2 monitoring in maintenance renal transplant recipients: Is it worthwhile? Transplantation 2003; 76: 1236-8.
40. 2 monitoring in the long-term management of renal transplant recipients. Transplantation 2003; 75: 2086-90.
41. Sitland T, Kiberd B, Lawen J et al. Conversion of longterm, Neoral treated kidney transplant recipients from C0 to C2 monitoring: six month follow-up. Am. J. Transplant 2002; 2 (Suppl. 3): 232.
42. Stefoni S, Midtved K, Cole E, Thervet E et al. Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporin a microemulsion: results of a 12-month, randomized, multicenter study. Transplantation 2005; 79: 577-83.